Department of Medicine, University of Calgary, Canada; Department of Obstetrics and Gynaecology University of Calgary, Canada.
Centre for Implementation Research, Ottawa Hospital Research Institute, Canada; Faculty of Health Sciences, Queen's University, Canada.
Best Pract Res Clin Obstet Gynaecol. 2021 Oct;76:83-95. doi: 10.1016/j.bpobgyn.2021.03.008. Epub 2021 Mar 22.
Vaccination in pregnancy (VIP) is dually beneficial - it protects the mother and the baby from tetanus, influenza, and pertussis. VIP uptake is low in many countries. Vaccine hesitancy, defined by the World Health Organization (WHO) as a "delay in acceptance or refusal of vaccination despite the availability of vaccination services" is one of WHO's ten threats to global health per 2019. According to extensive research, mostly from high-income countries (HIC) and limited to tetanus, influenza and pertussis vaccines, lack of provider recommendations, safety concerns, and limitations in access are the main barriers to VIP. Health care provider recommendation is the leading facilitator for VIP across various socioeconomic status groups. Data on strategies to overcome patient, provider, and system barriers to VIP are inconsistent, contradictory, or lacking. Patient-focused research on evidence-based strategies to overcome provider and system barriers is needed. Furthermore, VIP programs require embedded continuous quality improvement to ensure sustainability.
孕期接种疫苗（VIP）具有双重益处——它可以保护母亲和婴儿免受破伤风、流感和百日咳的侵害。在许多国家，VIP 的接种率都很低。疫苗犹豫是世界卫生组织（WHO）定义的一种现象，即“尽管有疫苗接种服务，但仍延迟接受或拒绝接种疫苗”。根据广泛的研究，主要来自高收入国家（HIC），并且仅限于破伤风、流感和百日咳疫苗，缺乏提供者的建议、安全性问题以及获取途径的限制是 VIP 的主要障碍。医疗保健提供者的建议是 VIP 在各个社会经济地位群体中的主要促进因素。关于克服 VIP 患者、提供者和系统障碍的策略的数据不一致、相互矛盾或缺乏。需要针对基于证据的克服提供者和系统障碍的策略进行以患者为中心的研究。此外，VIP 计划需要嵌入持续质量改进，以确保可持续性。
